Amoxicillin

Generic Name: Amoxicillin

Brand Names: Amoxil, Augmentin, Clavulin, Moxatag, Omeclamox, Prevpac, Talicia, Voquezna 14 Day Dualpak 20;500, Voquezna 14 Day Triplepak 20;500;500

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₉N_₃O_₅S

CAS Number: 26787-78-0

Unique Ingredient Identifier: 9EM05410Q9

Background: Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to penicillin and ampicillin, but leads to higher serum concentrations than ampicillin.

Amoxicillin was granted FDA approval on 18 January 1974.

Indication: Amoxicillin alone is indicated to treat susceptible bacterial infections of the ear, nose, throat, genitourinary tract, skin, skin structure, and lower respiratory tract. Amoxicillin is given with calvulanic acid to treat acute bacterial sinusitis, community acquired pneumonia, lower respiratory tract infections, acute bacterial otitis media, skin and skin structure infections, and urinary tract infections. Amoxicillin is given with omeprazole in the treatment of Helicobacter pylori (H. pylori) infection.

Amoxicillin is used in combination with vonoprazan and clarithromycin as co-packaged triple therapy or in combination with vonoprazan as co-packaged dual therapy to treat H. pylori infection in adults.

Associated Conditions: Acute Bacterial Sinusitis (ABS), Acute Otitis Media (AOM), Bacterial Infections, Community Acquired Pneumonia (CAP), Duodenal ulcer caused by helicobacter pylori, Genitourinary tract infection, Helicobacter Pylori Infection, Lower Respiratory Tract Infection (LRTI), Peptic Ulcer With H. Pylori Infection, Sinusitis, Skin and Subcutaneous Tissue Bacterial Infections, Urinary Tract Infection, Acute, uncomplicated Gonorrhea, Ear, nose, and throat infections

Associated Therapies: -

Clinical Trials

Lactobacillus Reuteri in Management of Helicobacter Pylori Infection in Dyspeptic Patients

Not Applicable

Completed

Conditions: Helicobacter Pylori Infection

Interventions: Dietary Supplement: Lactobacillus reuteri
Dietary Supplement: Placebo
Drug: Omeprazole
Drug: Amoxicillin
Drug: Clarithromycin

First Posted Date: 2012-05-08

Last Posted Date: 2015-08-17

Lead Sponsor: Zagazig University

Target Recruit Count: 70

Registration Number: NCT01593592

Locations: 🇪🇬
Zagazig University Hospitals, Zagazig, Sharkia, Egypt

Gut Flora and Lipid Metabolism

Not Applicable

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: Placebo capsule
Drug: Amoxicillin

First Posted Date: 2012-03-29

Last Posted Date: 2013-05-14

Lead Sponsor: Maastricht University Medical Center

Target Recruit Count: 77

Registration Number: NCT01566266

Locations: 🇳🇱
Maastricht University Medical Center, Maastricht, Limburg, Netherlands

Community Based Management of Fast Breathing in Infants Aged < 60 Days in Low-income Settlements of Karachi

Phase 4

Terminated

Conditions: Fast Breathing in Young Infants

Interventions: Drug: Amoxicillin
Drug: Sugar Syrup

First Posted Date: 2012-02-15

Last Posted Date: 2014-06-03

Lead Sponsor: Aga Khan University

Target Recruit Count: 963

Registration Number: NCT01533818

Locations: 🇵🇰
Primary Health Centers, Karachi, Sind, Pakistan

The Effect of Amoxicillin Versus Placebo on Gastrointestinal Motility in Children

Not Applicable

Completed

Conditions: Functional Gastrointestinal Disorders

Interventions: Other: Placebo
Drug: Amoxicillin

First Posted Date: 2012-02-09

Last Posted Date: 2022-09-22

Lead Sponsor: Nationwide Children's Hospital

Target Recruit Count: 33

Registration Number: NCT01530009

Locations: 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States

Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori

Phase 3

Completed

Conditions: H. Pylori Infection

Interventions: Drug: TAK-438
Drug: Lansoprazole
Drug: Amoxicillin
Drug: Clarithromycin

First Posted Date: 2012-01-06

Last Posted Date: 2013-11-05

Lead Sponsor: Takeda

Target Recruit Count: 650

Registration Number: NCT01505127

Effects of Pre-, Pro- & Anti-biotics on Gut Microbiota

Not Applicable

Completed

Conditions: Human Gut Microbiota

Interventions: Dietary Supplement: Trametes versicolor extract
Dietary Supplement: Saccharomyces boulardii
Drug: Amoxicillin

First Posted Date: 2011-08-11

Last Posted Date: 2017-07-24

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 32

Registration Number: NCT01414010

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Amoxicillin Versus Benzyl Penicillin for Treatment of Children Hospitalised With Severe Pneumonia

Phase 3

Completed

Conditions: Pneumonia

Interventions: Drug: Benzyl penicillin
Drug: Amoxicillin

First Posted Date: 2011-07-22

Last Posted Date: 2015-02-13

Lead Sponsor: KEMRI-Wellcome Trust Collaborative Research Program

Target Recruit Count: 561

Registration Number: NCT01399723

Locations: 🇰🇪
New Nyanza Provincial General Hospital, Kisumu, Nyanza, Kenya
🇰🇪
Kisumu East District Hospital, Kisumu, Nyanza, Kenya
🇰🇪
Kerugoya District Hospital, Kerugoya, Central, Kenya

and more 3 locations